In this episode of the Better Science Better Health podcast, Gwen and Petra hit play on another dense stretch of the Vital Health Podcast with Melanie Whittington and start translating the language that quietly steers the whole conversation. The kind of terms that sound technical but end up deciding who gets what treatment, and when.

They walk through the core ideas in health economics and policy, from DMTs and HTAs to QALYs, EVLYs, ICER, and the GRACE model, showing how each one acts like a lens on value, access, and real-world treatment decisions. Not just definitions, but what these concepts actually do once they leave the page.

They also dig into the role of agencies like the FDA and EMA, and why two regulators can look at the same data and still land in different places. Same evidence, different judgment calls, shaped by how each system weighs risk, benefit, and uncertainty.

It is part translation, part reality check, turning dense terminology into something you can follow and question.

More on FDA vs EMA here: FDA vs EMA Approval: Why Decisions Can Differ